{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:27:47Z","timestamp":1794000467982,"version":"4.8.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.cpcardiol.2026.103470","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:04:00Z","timestamp":1790694240000},"page":"103470","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Emerging therapeutics in hypertension: Evidence, clinical readiness, and implementation"],"prefix":"10.1016","volume":"52","author":[{"given":"Jonsi","family":"Tavethia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8496-868X","authenticated-orcid":false,"given":"Darshan","family":"Shivanne Gowda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4847-4377","authenticated-orcid":false,"given":"Shubh","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baneet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Ghay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahil","family":"Ghay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Chowdhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6853-0791","authenticated-orcid":false,"given":"Kedar","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9090-5151","authenticated-orcid":false,"given":"Anshul","family":"Bhadania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5866-2566","authenticated-orcid":false,"given":"Kamal","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aravinda","family":"Nanjundappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Laffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10304","key":"10.1016\/j.cpcardiol.2026.103470_bib0001","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(21)01330-1","article-title":"Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants","volume":"398","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2026.103470_bib0002","unstructured":"Global report on hypertension 2025: high stakes: turning evidence into action [Internet]. [cited 2026 Sep 1]. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240115569."},{"issue":"38","key":"10.1016\/j.cpcardiol.2026.103470_bib0003","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.cpcardiol.2026.103470_bib0004","first-page":"e114","volume":"152","author":"Jones","year":"2025","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.cpcardiol.2026.103470_bib0005","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1712231","article-title":"Relationship between clinic and ambulatory blood-pressure measurements and mortality","volume":"378","author":"Banegas","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.cpcardiol.2026.103470_bib0006","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41371-019-0243-6","article-title":"Usefulness of ambulatory blood pressure measurement for hypertension management in India: the India ABPM study","volume":"34","author":"Kaul","year":"2020","journal-title":"J Hum Hypertens"},{"issue":"3","key":"10.1016\/j.cpcardiol.2026.103470_bib0007","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/HJH.0b013e32835ca8dd","article-title":"Clinical usefulness and cost effectiveness of home blood pressure telemonitoring: meta-analysis of randomized controlled studies","volume":"31","author":"Omboni","year":"2013","journal-title":"J Hypertens"},{"issue":"7","key":"10.1016\/j.cpcardiol.2026.103470_bib0008","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/jhh.2016.99","article-title":"Effectiveness of home blood pressure telemonitoring: a systematic review and meta-analysis of randomized controlled studies","volume":"31","author":"Duan","year":"2017","journal-title":"J Hum Hypertens"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103470_bib0009","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1161\/HYPERTENSIONAHA.110.160911","article-title":"Role of home blood pressure monitoring in overcoming therapeutic inertia and improving hypertension control: a systematic review and meta-analysis","volume":"57","author":"Agarwal","year":"2011","journal-title":"Hypertension"},{"issue":"12","key":"10.1016\/j.cpcardiol.2026.103470_bib0010","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1097\/HJH.0000000000003483","article-title":"European Society of Hypertension recommendations for the validation of cuffless blood pressure measuring devices: European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability","volume":"41","author":"Stergiou","year":"2023","journal-title":"J Hypertens"},{"key":"10.1016\/j.cpcardiol.2026.103470_bib0011","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3389\/fcvm.2019.00040","article-title":"Cuff-less methods for blood pressure telemonitoring","volume":"6","author":"Bard","year":"2019","journal-title":"Front Cardiovasc Med"},{"issue":"9","key":"10.1016\/j.cpcardiol.2026.103470_bib0012","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/s41551-018-0287-x","article-title":"Monitoring of the central blood pressure waveform via a conformal ultrasonic device","volume":"2","author":"Wang","year":"2018","journal-title":"Nat Biomed Eng"},{"issue":"10367","key":"10.1016\/j.cpcardiol.2026.103470_bib0013","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(22)02034-7","article-title":"Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial","volume":"400","author":"Schlaich","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2026.103470_bib0014","unstructured":"TRYVIOTM (aprocitentan) tablets Approval Label [cited 2026 Sep 1]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/219878Orig1s000lbl.pdf."},{"key":"10.1016\/j.cpcardiol.2026.103470_bib0015","unstructured":"US Food and Drug Administration. Endothelin Receptor Antagonist REMS Information. [cited 2026 Sep 1]. Available from: https:\/\/www.fda.gov\/drugs\/information-drug-class\/endothelin-receptor-antagonist-rems-information."},{"issue":"5","key":"10.1016\/j.cpcardiol.2026.103470_bib0016","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa2213169","article-title":"Phase 2 trial of baxdrostat for treatment-resistant hypertension","volume":"388","author":"Freeman","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2026.103470_bib0017","unstructured":"Efficacy and Safety of Baxdrostat in Patients With Uncontrolled Hypertension: HALO Trial. Presented at the 72nd American College of Cardiology Scientific Session. ClinicalTrials.gov identifier \"NCT05137002\". No full peer-reviewed report of this trial has been published.[Cited 2026 Sep 1]. Available from: https:\/\/www.acc.org\/latest-in-cardiology\/clinical-trials\/2023\/03\/01\/23\/34\/halo."},{"issue":"14","key":"10.1016\/j.cpcardiol.2026.103470_bib0018","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJMoa2507109","article-title":"Efficacy and safety of baxdrostat in uncontrolled and resistant hypertension","volume":"393","author":"Flack","year":"2025","journal-title":"N Engl J Med"},{"issue":"10532","key":"10.1016\/j.cpcardiol.2026.103470_bib0019","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S0140-6736(25)02549-8","article-title":"Bax24 Investigators. Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"407","author":"Azizi","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2026.103470_bib0020","unstructured":"HIGHLIGHTS OF PRESCRIBING INFORMATION. [cited 2026 Sep 1]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/219878Orig1s000lbl.pdf."},{"issue":"12","key":"10.1016\/j.cpcardiol.2026.103470_bib0021","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1001\/jama.2023.16029","article-title":"Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension: The Target-HTN Randomized Clinical Trial","volume":"330","author":"Laffin","year":"2023","journal-title":"JAMA"},{"issue":"18","key":"10.1016\/j.cpcardiol.2026.103470_bib0022","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2501440","article-title":"Advance-HTN Investigators. Lorundrostat efficacy and safety in patients with uncontrolled hypertension","volume":"392","author":"Laffin","year":"2025","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.cpcardiol.2026.103470_bib0023","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1001\/jama.2025.9413","article-title":"Lorundrostat in participants with uncontrolled hypertension and treatment-resistant hypertension: the Launch-HTN randomized clinical trial","volume":"334","author":"Saxena","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.cpcardiol.2026.103470_bib0024","unstructured":"Mineralys Therapeutics, Inc. [Internet]. 2026 [cited 2026 Sep 1]. Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results. Available from: https:\/\/ir.mineralystx.com\/news-events\/press-releases\/detail\/93\/mineralys-therapeutics-announces-fda-acceptance-of-nda."},{"issue":"3","key":"10.1016\/j.cpcardiol.2026.103470_bib0025","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2208391","article-title":"Zilebesiran, an RNA interference therapeutic agent for hypertension","volume":"389","author":"Desai","year":"2023","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.cpcardiol.2026.103470_bib0026","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1001\/jama.2024.0728","article-title":"RNA interference with zilebesiran for mild to moderate hypertension: The KARDIA-1 randomized clinical trial","volume":"331","author":"Bakris","year":"2024","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103470_bib0027","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1001\/jama.2025.6681","article-title":"Add-on treatment with zilebesiran for inadequately controlled hypertension: the KARDIA-2 randomized clinical trial","volume":"334","author":"Desai","year":"2025","journal-title":"JAMA"},{"issue":"Suppl 1","key":"10.1016\/j.cpcardiol.2026.103470_bib0028","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1097\/01.hjh.0001020524.16638.68","article-title":"Kardia-3 study design: zilebesiran as add-on therapy in patients with high cardiovascular risk and hypertension inadequately controlled by standard of care antihypertensives","volume":"42","author":"Havasi","year":"2024","journal-title":"J Hypertens"},{"key":"10.1016\/j.cpcardiol.2026.103470_bib0029","unstructured":"European Society of Cardiology. KARDIA-3 trial examines blood-pressure-lowering effects of zilebesiran in hypertensive patients at high cardiovascular risk [press release]. 2025.[cited 2026 Sep 1] [Full Text Paper not released] Availaible from: https:\/\/www.escardio.org\/news\/press\/press-releases\/KARDIA-3-trial-examines-blood-pressure-lowering-effects-of-zilebesiran-in-hypertensive-patients-at-high-cardiovascular-risk\/."},{"key":"10.1016\/j.cpcardiol.2026.103470_bib0030","unstructured":"ClinicalTrials.gov. Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease (ZENITH). ClinicalTrials.gov ID NCT07181109 [cited 2026 Sep 1]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07181109."},{"issue":"15","key":"10.1016\/j.cpcardiol.2026.103470_bib0031","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJMoa1402670","article-title":"A controlled trial of renal denervation for resistant hypertension","volume":"370","author":"Bhatt","year":"2014","journal-title":"N Engl J Med"},{"issue":"10234","key":"10.1016\/j.cpcardiol.2026.103470_bib0032","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/S0140-6736(20)30554-7","article-title":"Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial","volume":"395","author":"B\u00f6hm","year":"2020","journal-title":"Lancet"},{"issue":"10137","key":"10.1016\/j.cpcardiol.2026.103470_bib0033","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1016\/S0140-6736(18)31082-1","article-title":"Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial","volume":"391","author":"Azizi","year":"2018","journal-title":"The Lancet"},{"issue":"10137","key":"10.1016\/j.cpcardiol.2026.103470_bib0034","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1016\/S0140-6736(18)31082-1","article-title":"Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial","volume":"391","author":"Azizi","year":"2018","journal-title":"The Lancet"},{"issue":"10293","key":"10.1016\/j.cpcardiol.2026.103470_bib0035","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/S0140-6736(21)00788-1","article-title":"RADIANCE-HTN Investigators. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial","volume":"397","author":"Azizi","year":"2021","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.cpcardiol.2026.103470_bib0036","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/j.jacc.2023.08.045","article-title":"Safety and efficacy of renal denervation in patients taking antihypertensive medications (SPYRAL HTN-ON MED Expansion)","volume":"82","author":"Kandzari","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.cpcardiol.2026.103470_bib0037","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.126.049081","article-title":"Three-year durability of radiofrequency renal denervation: SPYRAL HTN-ON MED","volume":"15","author":"Kandzari","year":"2026","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cpcardiol.2026.103470_bib0038","unstructured":"US Food and Drug Administration. Paradise Ultrasound Renal Denervation System: P220023 [cited 2026 Sep 1]. Available from: https:\/\/www.fda.gov\/medical-devices\/recently-approved-devices\/paradise-ultrasound-renal-denervation-system-p220023."},{"key":"10.1016\/j.cpcardiol.2026.103470_bib0039","unstructured":"US Food and Drug Administration. Symplicity Spyral renal denervation system:Premarket Approval (PMA). [cited 2026 Sep 1 ]. Available from: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpma\/pma.cfm?id=P220026."},{"key":"10.1016\/j.cpcardiol.2026.103470_bib0040","unstructured":"Centers for Medicare and Medicaid Services.Renal Denervation for Uncontrolled Hypertension. [cited 2026 Sep 1]. Available from: https:\/\/www.cms.gov\/medicare\/coverage\/coverage-evidence-development\/renal-denervation-uncontrolled-hypertension."},{"issue":"3","key":"10.1016\/j.cpcardiol.2026.103470_bib0041","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/j.1460-2075.1992.tb05119.x","article-title":"High blood pressure in transgenic mice carrying the rat angiotensinogen gene","volume":"11","author":"Kimura","year":"1992","journal-title":"EMBO J"},{"issue":"5","key":"10.1016\/j.cpcardiol.2026.103470_bib0042","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/hr.2013.155","article-title":"Targeting of hepatic angiotensinogen using chemically modified siRNAs results in significant and sustained blood pressure lowering in a rat model of hypertension","volume":"37","author":"Olearczyk","year":"2014","journal-title":"Hypertens Res"},{"issue":"3 Pt 1","key":"10.1016\/j.cpcardiol.2026.103470_bib0043","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1161\/01.HYP.30.3.307","article-title":"Prolonged reduction of high blood pressure with human nitric oxide synthase gene delivery","volume":"30","author":"Lin","year":"1997","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.cpcardiol.2026.103470_bib0044","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1172\/JCI117847","article-title":"Direct gene delivery of human tissue kallikrein reduces blood pressure in spontaneously hypertensive rats","volume":"95","author":"Wang","year":"1995","journal-title":"J Clin Invest"},{"issue":"39","key":"10.1016\/j.cpcardiol.2026.103470_bib0045","doi-asserted-by":"crossref","first-page":"13789","DOI":"10.1073\/pnas.0506807102","article-title":"Regulatable atrial natriuretic peptide gene therapy for hypertension","volume":"102","author":"Schillinger","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.cpcardiol.2026.103470_bib0046","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1161\/ATVBAHA.116.307227","article-title":"CRISPR-Cas9 targeting of PCSK9 in human hepatocytes in vivo","volume":"36","author":"Wang","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7859","key":"10.1016\/j.cpcardiol.2026.103470_bib0047","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41586-021-03534-y","article-title":"In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates","volume":"593","author":"Musunuru","year":"2021","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.cpcardiol.2026.103470_bib0048","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/ng.3768","article-title":"Genome-wide association analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk","volume":"49","author":"Warren","year":"2017","journal-title":"Nat Genet"},{"issue":"10","key":"10.1016\/j.cpcardiol.2026.103470_bib0049","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1038\/s41588-018-0205-x","article-title":"Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits","volume":"50","author":"Evangelou","year":"2018","journal-title":"Nat Genet"},{"issue":"8","key":"10.1016\/j.cpcardiol.2026.103470_bib0050","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1161\/HYPERTENSIONAHA.122.19324","article-title":"Insights from a large-scale whole-genome sequencing study of systolic blood pressure, diastolic blood pressure, and hypertension","volume":"79","author":"Kelly","year":"2022","journal-title":"Hypertension"},{"issue":"8","key":"10.1016\/j.cpcardiol.2026.103470_bib0051","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.2217\/pgs.09.61","article-title":"Pharmacogenetics of antihypertensive treatment: detailing disciplinary dissonance","volume":"10","author":"Arnett","year":"2009","journal-title":"Pharmacogenomics"},{"issue":"9","key":"10.1016\/j.cpcardiol.2026.103470_bib0052","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1161\/CIR.0000000000000226","article-title":"Transformative impact of proteomics on cardiovascular health and disease: a scientific statement from the American Heart Association","volume":"132","author":"Lindsey","year":"2015","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.cpcardiol.2026.103470_bib0053","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1177\/2047487316645469","article-title":"Translational and emerging clinical applications of metabolomics in cardiovascular disease diagnosis and treatment","volume":"23","author":"Dona","year":"2016","journal-title":"Eur J Prev Cardiol"},{"issue":"4","key":"10.1016\/j.cpcardiol.2026.103470_bib0054","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3390\/ijms17040451","article-title":"Epigenetic modifications in essential hypertension","volume":"17","author":"Wise","year":"2016","journal-title":"Int J Mol Sci"},{"issue":"22","key":"10.1016\/j.cpcardiol.2026.103470_bib0055","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Wright","year":"2015","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.cpcardiol.2026.103470_bib0056","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","volume":"362","author":"Cushman","year":"2010","journal-title":"N Engl J Med"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280626002112?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280626002112?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:01:53Z","timestamp":1793998913000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280626002112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2027,1]]}},"alternative-id":["S0146280626002112"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2026.103470","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging therapeutics in hypertension: Evidence, clinical readiness, and implementation","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2026.103470","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"103470"}}